

British Columbia (BC) Influenza Surveillance Bulletin

2020-21 Influenza Season

Week 8: February 21 to 27, 2021

Table of Contents

A. Laboratory surveillance

Laboratory findings [2](#)

B. Clinical Indicators

BC Children's Hospital Emergency Room [7](#)

Medical Service Plan [7](#)

C. Influenza outbreak reports

[9](#)

D. National

FluWatch Activity levels [10](#)

NML Strain Characterization [10](#)

NML Antiviral Resistance [10](#)

E. International

USA (CDC) [11](#)

WHO [11](#)

F. Influenza Vaccine Components (WHO Recommendations)

2019-20 Northern Hemisphere [12](#)

2021 Southern Hemisphere [12](#)

G. Additional Information

Explanatory note [13](#)

List of Acronyms [13](#)

Web Sites [13](#)

Further into the 2020-21 season, and still no sign of influenza virus circulation in BC

Since the start of the 2020-21 season (in week 40, beginning September 27, 2020) through to the end of week 8 (February 27, 2021), there have been no influenza cases detected in BC, despite over 50,000 specimens undergoing clinical diagnostic testing for the virus.

Since week 40, 17 influenza viruses (9 influenza A and 8 influenza B) have been found among 10 individuals. All 10 individuals, however, had recently received the live attenuated influenza vaccine (LAIV), suggesting vaccine-type rather than wild-type virus. Detecting vaccine virus shortly after LAIV receipt is not unexpected.

By contrast, for the same week 40 to week 8 period of the past 5 (2015-2019) seasons, there were on average 14,394 tests conducted and 3,509 influenza detections per season (range 1,694 to 4,812). Average week 8 influenza positivity for the past 5 seasons was 33%. Accordingly, testing for influenza virus this season is way up, but detection is way down.

No long-term care facility (LTCF) influenza outbreaks have been reported in 2020-21 compared to 47 LTCF outbreaks between week 40 and week 8 of the 2019-20 season.

There have also been no RSV detections this season (since week 40). Enteroviruses (EV/RV) are still the most common non-influenza respiratory virus (NIRV) this season, representing 1,075/1,212 (87%) of NIRV detections (excluding SARS-CoV-2).

The World Health Organization (WHO) has updated their recommendations for the 2021-22 northern hemisphere influenza vaccine. More details [here](#).

Prepared by BCCDC Influenza & Emerging Respiratory Pathogens Team

Report Disseminated: March 4, 2021

A. Laboratory Surveillance


There have been 5 influenza viruses detected among the 22,418 specimens tested between week 1 (beginning January 3, 2021) and week 8 (ending February 27, 2021) ([Figure 1](#)). These 5 detections were associated with recent live attenuated influenza vaccine (LAIV) in 3 individuals and likely represent vaccine-type rather than wild-type virus circulation. So far, there are still no influenza cases detected among specimens undergoing clinical diagnostic testing for influenza virus during the 2020-21 season in BC.

During the most recent week 8 (February 21-27, 2021) of the 2020-21 season, there were no influenza detections among 3,129 specimens tested by laboratories across BC (none positive); by contrast, in week 8 of the prior 2019-20 season there were 433 influenza virus detections among 1,698 tests conducted. Compared to prior seasons, the influenza positivity rate (0%) is well below the 5-year historical average for week 8 (33.2%) ([Figure 2](#)).

Since the start of the 2020-21 influenza season in week 40 (beginning September 27, 2020) to the end of the current reporting week 8, over 50,000 influenza tests having been conducted across BC laboratories ([Table 1](#)). During this period, a total of 17 influenza viruses (9 influenza A and 8 influenza B) were detected between weeks 44-7 (October 25, 2020-February 20, 2021), from among 10 individuals each of whom had recently received the LAIV and they likely do not represent community circulation of wild-type influenza viruses.

By way of contrast, during the same period of 2019-20, there were 23,326 influenza tests conducted with 3,668 (16%) influenza viruses detected (additionally noting that LAIV was not administered as part of the publicly-funded influenza immunization program in 2019-20). During the same week 40-8 period of the past 5 (2015-2019) seasons an average of 14,394 influenza tests and 3,509 (24%) influenza detections (range 1,694 to 4,812 detections) were reported (source: [RVDSS Report](#)).

Figure 1. Influenza virus positivity among respiratory specimens tested^a across BC, 2020-2021^{b,c,d}




- The percentage influenza positivity is presented by influenza type based on primary specimens submitted for influenza testing at the BCCDC Public Health Laboratory (PHL) and other external sites that share complete testing data with the BCCDC PHL. Reporting sites include: BC Children's and Women's Hospital, Children's and Women's Hospital Laboratory, Fraser Health Medical Microbiology Laboratory, Island Health, Providence Health Care, Powell River Hospital, St. Paul's Hospital, Vancouver General Hospital, Victoria General Hospital, Vancouver Coastal Health, BCCDC PHL, Interior Health Authority sites, and Northern Health Authority.
- Rates are subject to change with subsequent data reconciliation.
- Week of sample based on the sample collection date.
- The positive influenza A and influenza B viruses detected in weeks 44, 47, 48, 49, 3, 6, and 7 are all associated with live attenuated influenza vaccine (LAIV) receipt in 10 individuals, and likely represent vaccine-type virus rather than community circulation of seasonal influenza.

The BCCDC Public Health Laboratory (PHL) and some local health authority laboratories also conduct testing for other non-influenza respiratory viruses (NIRV), including RSV +/- other multiplex testing (beyond SARS-CoV-2 which is not addressed in this report). Weekly RSV and EV/RV positivity rates have been below the 5-year historical average (2015-16 to 2019-2020) and in most weeks, remain below respective 5-year minimum values (Figure 2).

Of 3,123 respiratory specimens that were tested for RSV in week 8, none were positive. In fact, there have been no RSV detections this season among 52,223 specimens tested since week 40. The last RSV detection was in week 38 (involving an adult age 60-69 years detected in week 38 [Sept 13-19, 2020]). Of week 8 specimens additionally subjected to multiplex testing, entero/rhinoviruses (EV/RV) were found in 5.5% (28/507) and were the most commonly detected NIRV (28/34; 82%). Cumulatively this season, EV/RV were detected in 1,075/11,628 (9%) specimens tested, which is still lower than 1,103/5,800 (19%) from the 2019-2020 season. In 2020-21 EV/RV represent 1,075/1,212 (87%) of NIRV detections with most EV/RV detections being among young children with median age of 3 years. (Figures 2, 3, 4, 5; Table 1).


Figure 2. Laboratory influenza and other respiratory virus detections across BC with 5-season historical data***



* The shaded area (red) represents the maximum and minimum percentage of influenza positivity reported by week from seasons 2015-2016 to 2019-2020. Source: Respiratory Virus Detections Surveillance System (RVDSS) weekly report; data includes seasons 2015-16, 2016-17, 2017-18, 2019-20, 2020-21.

** Historical average data for week 53 is calculated by taking the average of week 52 and week 1 data from the past 5 influenza seasons.


Figure 3. Influenza and non-influenza respiratory virus (NIRV) detections among specimens submitted to BCCDC Public Health Laboratory and Island Health Laboratories, 2020-2021*



* The BCCDC Public Health Laboratory (PHL) conducts the majority of influenza subtype characterization for the province, including for primary specimens submitted directly to the BCCDC PHL for influenza diagnosis, as well as for specimens that have tested positive for influenza at other external sites and for which secondary subtyping was requested. Influenza A(H1N1)pdm09 and influenza A(subtype unknown) weekly case counts as directly typed/subtyped on primary specimens by Island Health Authority are also incorporated into the influenza counts in the graph and narrative summary above.


** The positive influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B viruses detected in weeks 44, 47, 48, 49, 3, 7, and 7 are all associated with live attenuated influenza vaccine (LAIV) receipt in 10 individuals. These detections have already been reported by local health authority laboratories (Figure 1, Figure 5, and Table 1) and were sent to BCCDC PHL for further subtyping and analysis.

Figure 4. Cumulative number (since week 36) of non-influenza respiratory virus detections (NIRV) by type and age group, BCCDC Public Health Laboratory, 2020-21



Source: BCCDC Public Health Laboratory (PHDRW); Data are current to March 4, 2021; figure includes cumulative influenza detections for specimens collected from weeks 36-8.

Figure 5. Influenza and NIRV detections among respiratory specimens submitted to BC Children’s and Women’s Health Centre Laboratory, 2020-2021^{a,b,c,d}



- a. Positive rates were calculated using aggregate data. The denominators for each rate represent the total number of tests; multiple tests may be performed for a single specimen and/or patient.
- b. Week of sample based on the sample collection date.
- c. From week 36 (August 30-September 5, 2020) to week 8 (February 21-27, 2021), among the 791 specimens submitted for influenza virus testing at the BC Children’s and Women’s Health Centre laboratory, most that were found positive for non-influenza respiratory viruses were entero/rhinoviruses (215/235= 91.5%). No specimen was positive for RSV.
- d. The positive influenza A and influenza B viruses detected in week 44 and 47 are associated with live attenuated influenza vaccine (LAIV) receipt in 2 individuals, and likely represent vaccine-type virus rather than community circulation of seasonal influenza viruses.

Table 1. Influenza and non-influenza respiratory viruses (NIRV) detected among primary patient specimens by health authority of test site

Count (% positive from total screened)	Health authority ^{a,b} where specimen tested ^c , BC Cases						Total
	FHA	IHA	VIHA	NHA	VCHA	BCCDC/ CW	
Current report Week 8 [February 21, 2021 – February 27, 2021]							
Influenza, Total^d	0/1332 (0)	0/538 (0)	0/836 (0)	0/0 (.)	0/222 (0)	0/201 (0)	0/3129 (0)
Influenza A total	0 (0)	0 (0)	0 (0)	0 (.)	0 (0)	0 (0)	0 (0)
A(H3N2) ^e	0	0	0	0	0	----	0
A(H1N1)pdm09 ^e	0	0	0	0	0	----	0
Influenza B total	0 (0)	0 (0)	0 (0)	0 (.)	0 (0)	0 (0)	0 (0)
NIRV, Total^c	0	4	1	0	3	26	34
RSV	0/1332 (0)	0/538 (0)	0/836 (0)	0/1 (.)	0/215 (0)	0/201 (0)	0/3123 (0)
Enterov/Rhinovirus	--- ^f	3/79 (3.8)	1/66 (1.5)	--- ^f	3/84 (3.6) ^g	21/278 (7.6)	---
Other ^h	--- ^f	1/79 (1.3)	0/66 (0)	--- ^f	0/91 (0) ^g	5/278 (1.4)	---
2020-21 Season: Cumulative total to date, Week 40 to 8 [September 27, 2020 – February 27, 2021]							
Influenza Total^d	0/14531 (0)	5/ 7497 (0.1) ⁱ	2/14619 (<0.1) ⁱ	2/82 (2.4) ⁱ	0/4508 (0)	8/11130 (0.1) ⁱ	17/52367 (<0.1) ⁱ
Influenza A total	0 (0)	3 (<0.1)	1 (<0.1) ⁱ	1 (1.2)	0 (0)	4 (<0.1) ⁱ	9 (<0.1) ⁱ
A(H3N2) ^e	0	2	1	2	3	----	8
A(H1N1)pdm09 ^e	0	1	1	0	1	----	3
Influenza B total	0 (0)	2 (<0.1)	1 (<0.1) ⁱ	1 (1.2)	0 (0)	4 (<0.1)	8 (<0.1) ⁱ
Cumulative influenza incidence (/100,000)^j	0	0.6	0.2	0.7	0	---	0.3
NIRV, Total^c	0	496	64	0	27	625	1212
RSV	0/14531 (0)	0/7497 (0)	0/14619 (0)	0/82 (0)	0/4364 (0)	1/11130 (<0.1)	1/52223 (<0.1)
Enterov/Rhinovirus	--- ^f	468/4672 (10.0)	36/776 (4.6)	--- ^f	24/894 (2.7) ^g	547/5286 (10.3)	---
Other ^h	--- ^f	28/4206 (0.7)	28/776 (3.6)	--- ^f	3/1148 (0.3) ^g	77/5286 (1.5)	---


- FHA=Fraser Health Authority; IHA=Interior Health Authority; VIHA= Vancouver Island Health Authority; NHA=Northern Health Authority; VCHA=Vancouver Coastal Health Authority; BCCDC= primary patient specimens screened at BCCDC Public Health Laboratory; CW=Children’s and Women’s Health Centre Laboratory
- The HA associated with each subtyped sample is based on patient’s health authority. If patient health authority information is missing, the ordering physician’s health authority is used.
- The number of influenza A, influenza B, RSV, Enterov/Rhinovirus, and other non-influenza respiratory viruses (NIRV) detected are based on specimens submitted for influenza screening/testing to various labs across FHA, VCHA (including Providence Health), VIHA, IHA and NHA. Samples sent to Children’s & Women’s Laboratory (CW) and BCCDC Public Health Laboratory for primary diagnostic purposes are displayed separately here (i.e. excluding those already screened at another site and submitted for secondary testing or characterization).
- Influenza co-infections (influenza A and B virus positive) not accounted for in data source (PLOVER).
- The BCCDC PHL conducts the majority of influenza subtype characterization for the province, including for primary specimens submitted directly to the BCCDC PHL for influenza diagnosis, as well as for specimens that have tested positive for influenza at other external sites and for which secondary subtyping was requested. Influenza A(H1N1)pdm09 and influenza A(H3N2) are directly typed/subtyped on primary specimens by IHA and are also incorporated into the influenza A subtype counts above.
- Not tested by Fraser Health Microbiology Laboratories and Northern Health laboratory sites.
- Enterov/Rhinovirus and Coronavirus not tested by Providence Health.
- Other non-influenza respiratory viruses (NIRV) included on multiplex panels are parainfluenza, adenovirus, human metapneumovirus (HMPV), and seasonal coronaviruses (does not include SARS-CoV-2).
- Since the start of the season (week 40), there has been 10 laboratory reported cases known to be associated with recent live attenuated influenza vaccine (LAIV) receipts. The reported LAIV cases correspond with all the influenza A and B virus detections between weeks 44-7; majority of these cases have dual influenza A and B virus detections.
- Cumulative incidence of influenza is calculated from dividing total influenza cases (starting week 40) by the total population size of each health authority and BC (PEOPLE2020 population estimates).

B. Clinical Indicators

BC Children’s Hospital Emergency Room

Continuing a pattern since week 13 of the 2019-20 season, the proportion of visits to BC Children’s Hospital Emergency Room (BCCH ER) in week 8 of the 2020-21 season attributed to ILI (2.5%) remains substantially below the 5-year historical average (16.7%) (Figure 6). This may be due to changes in health seeking behaviour and social distancing during the COVID-19 epidemic.

Figure 6. Percent of patients presenting to BC Children’s Hospital ER




Source: BCCH Admitting, Discharge, Transfer database (ADT). Data includes records with a triage chief complaint of "flu" or "influenza" or "fever/cough."
*5-year historical average for 2020-21 season based on 2014-15 to 2018-19 seasons (excluded 2019-20 season); CI=confidence interval.

Medical Service Plan


As shown in Figure 7 and Figure 8, in all weeks between week 1 (beginning January 3, 2021) and week 8 (beginning February 21, 2021), BC Medical Service Plan (MSP) general practitioner claims for influenza illness (weekly counts) were well below the expected range in BC and in all 5 health authorities. For earlier weeks that exceeded the expected range, note that there are many non-influenza virus causes of similar clinical influenza-like illness. The clinical diagnosis of "influenza illness" as represented in administrative MSP billing data is non-specific and in the absence of laboratory-confirmed influenza detections in the province for many months more likely reflects these other non-influenza respiratory pathogens such as SARS-CoV-2 or entero/rhinoviruses. See laboratory findings .

Figure 7. Service claims submitted to MSP for influenza illness[‡], British Columbia, 2020-2021 season



[‡] Data provided by Population Health Surveillance and Epidemiology, BC Ministry of Health Services. Influenza illness (II) is tracked as the weekly count of all submitted MSP general practitioner claims with ICD-9 code 487 (influenza). MSP data beginning August 2, 2020 corresponds to sentinel ILI week 32; data are current to February 27, 2021.

Figure 8.



C. Influenza outbreak reports

The last influenza outbreak in BC was in March 2020 (week 12) with no influenza outbreaks reported thus far during the 2020-2021 season (since week 40, starting September 27, 2020). By way of comparison, during the same period spanning weeks 40 (from September 29, 2019) to 8 (to February 27, 2021) of 2019/2020 season, there were 47 long-term care facility (LTCF) influenza outbreaks reported.

D. National

FluWatch (week 7, February 14, 2021 to February 20, 2021)

All indicators of influenza activity remain exceptionally low for this time of year, despite continued monitoring for influenza across Canada. In week 7, 12,226 participants reported to FluWatchers and 7 (0.06%) participants reported cough and fever, which is still very low levels and may be a direct effect of individual and public health measures enacted to reduce the spread of COVID-19. Close to 20,000 tests for influenza were performed at reporting laboratories during week 7, which is almost double the average (10,842) for this time of the year (six year average). The percentage of test positives for influenza in week 7 was 0.02%, compared to the average 25.1% from the past six influenza seasons.

To date this season, 63 influenza detections have been reported, which is significantly lower than the past six seasons where an average of 32,703 influenza detections were reported between weeks 35-7. Thirty-one of the 63 influenza detections are known to be associated with live attenuated influenza vaccine (LAIV) receipt and do not represent community circulation of influenza viruses.

Since the start of the 2020-2021 influenza season, 115 influenza-like-illness (ILI) outbreaks have been reported; all outbreaks were in schools and/or daycares. Note outbreaks of ILI are not specific to any one respiratory pathogen and can be due to influenza or other respiratory viruses, including rhinovirus and even COVID-19. For more information on the respiratory viruses currently circulating in Canada, please refer to the [Respiratory Virus Detections in Canada Report](#).

FluWatch report (week 7) is available at: <https://www.canada.ca/en/public-health/services/diseases/flu-influenza/influenza-surveillance/weekly-influenza-reports.html>

National Microbiology Laboratory (NML): Strain Characterization

The National Microbiology Laboratory has not yet reported influenza strain characterization results for influenza viruses collected during the 2020-21 season.

National Microbiology Laboratory (NML): Antiviral Resistance

The National Microbiology Laboratory has not yet reported antiviral resistance results for influenza viruses collected during the 2020-21 season.

E. International

USA (week 7, February 14, 2021 to February 20, 2021)

In week 7, seasonal influenza activity in the United States remains lower than usual for this time of year. The proportion of outpatient visits for ILI was 1.0% that week, which is still below the national baseline (2.6%). Of the 12,280 specimens tested by public health laboratories in week 7, 2 (0.02%) influenza A (subtype unknown) and 0 (0%) influenza B viruses were detected. Cumulatively since week 40, a total of 312,844 specimens were tested and 123 (0.04%) were influenza A and 79 (0.03%) were influenza B positive. In clinical laboratories across the US, 18,740 samples were tested for influenza in week 7, 13 (0.07%) were influenza A and 15 (0.08%) were influenza B positive. Influenza virus characterization and influenza-associated hospitalization indicators will be available later this season. The proportion of deaths attributed to pneumonia, influenza, and COVID-19 during week 7 (19.3%) were above the epidemic threshold of 7.2%. No influenza-associated pediatric death has been reported to the US CDC in the current reporting week; the total for 2020-2021 season is one.

The US CDC has posted a summary of influenza activity in the United States and elsewhere, available at: <https://www.cdc.gov/flu/weekly/index.htm>.

WHO (March 1, 2021, based on data up to February 14, 2021)

In the temperate zone of the northern hemisphere, influenza activity remained below baseline with sporadic detections. In Canada and the United States of America, influenza activity indicators were at very low levels, despite testing at usual or increased levels. Respiratory illness indicators in Europe slightly increased in some reporting countries, but likely related to SARS-CoV-2 circulation. Central Asia and Northern Africa reported no influenza detections during the current reporting period. Western and East Asia reported low/below baseline influenza and ILI activity and sporadic detection of influenza A(H3N2) and influenza B.

In countries in the temperate zone of the southern hemisphere, influenza activity remained at inter-seasonal level. In Oceania, respiratory syncytial virus (RSV) continued to be reported at higher levels than the average of previous years in parts of Australia. No influenza but RSV detections were reported from South Africa sites. Reporting countries from temperate South America reported no influenza detections during this period.

In countries in the tropical zone, there was sporadic detection of influenza in some reporting regions. Multiple regions in the tropical zones, including Caribbean and Central America, South America, Tropical Africa, and Tropical Asia, reported sporadic detection of influenza A (including subtypes A(H1N1)pdm09 and A(H3N2)) and influenza B. Respiratory illness indicators have remained elevated in some countries while it decreased in others.

From February 1 to February 14, 2021, the WHO GISRS laboratories tested more than 237,021 specimens. Of these, 382 were positive for influenza viruses including 137 (35.9%) typed as influenza A and 245 (64.1%) as influenza B. Of subtyped influenza A viruses, 43 (52.4%) were influenza A(H1N1)pdm09 and 39 (47.6%) were influenza A(H3N2). Of the characterized B viruses, 1 (0.5%) belonged to the B(Yamagata) lineage and 182 (99.5%) to the B(Victoria) lineage.

Details are available at:

https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/.

F. WHO Recommendations for Influenza Vaccines

WHO Recommendations for the 2021-22 Northern Hemisphere Influenza Vaccine

On February 26, 2021, the WHO announced recommended strain components for the 2021-22 northern hemisphere trivalent influenza vaccine (TIV):*

- an A/Victoria/2570/2019 (H1N1)pdm09-like virus [a clade 6B.1A5A virus]; †
- an A/Cambodia/e0826360/2020 (H3N2)-like virus [a clade 3C.2a1b/T131K virus]; ‡
- a B/Washington/02/2019-like (B/Victoria lineage) virus [a clade V1A.3, Δ3 virus]. §

It is recommended that quadrivalent influenza vaccines (QIV) for the 2021-22 northern hemisphere season contain the above three viruses and a B/Phuket/3073/2013-like virus (B/Yamagata lineage) [a clade 3 virus], unchanged since 2015-2016.

* Recommended strains represent a change for two of the three components used for the 2020-2021 northern hemisphere TIV.

† Note for cell-based vaccine, the WHO recommends an A/Wisconsin/588/2019 (H1N1)pdm09-like virus [a clade 6B.1A5A virus] for the 2021-22 season. Recommended strains represent a change from the 2020-2021 season vaccine which contained an A/Guangdong-Maonan/SWL1536/2019 [a clade 6B.1A5A virus] for the egg-based vaccine and an A/Hawaii/70/2019 (H1N1)pdm09-like virus [also clade 6B.1A5A] for the cell-based vaccine.

‡ Recommended strain represents a change from the 2020-2021 season vaccine which contained an A/Hong Kong/2671/2019 (H3N2)-like virus [a clade 3C.2a1b/T135K virus].

§ Recommended strain is unchanged from the 2020-2021 season vaccine.

For further details: https://www.who.int/influenza/vaccines/virus/recommendations/2021-22_north/en/

WHO Recommendations for 2021 Southern Hemisphere Influenza Vaccine

On September 25, 2020, the WHO announced the recommended strain components for the 2021 southern hemisphere trivalent influenza vaccine (TIV)*:

- an A/Victoria/2570/2019 (H1N1)pdm09-like virus [a clade 6B.1A5A virus]; †
- an A/Hong Kong/2671/2019 (H3N2)-like virus [a clade 3C.2a1b/T135K virus]; ‡
- a B/Washington/02/2019 (B/Victoria lineage)-like virus [a clade V1A.3, Δ3 virus].

It is recommended that quadrivalent influenza vaccines (QIV) for the 2021 southern hemisphere season contain the above three viruses and a B/Phuket/3073/2013-like virus (B/Yamagata lineage) [a clade 3 virus], unchanged from 2020.

* Recommended strains represent a change for two of the three components used for the 2020 southern hemisphere TIV

† Note for cell-based vaccine, the WHO recommends A/Wisconsin/588/2019 (H1N1)pdm09-like virus [also a clade 6B.1A5A virus] for the 2020-21 season. Recommended strain represents a change from the 2020 season vaccine which contained an A/Brisbane/02/2018 (H1N1)pdm09-like virus [a clade 6B.1A1 virus]

‡ Note for cell-based vaccine, the WHO recommends an A/Hong Kong/45/2019 (H3N2)-like virus [also clade 3C.2a1b/T135K virus] for the 2020-21 season. Recommended strain represents a change from the 2020 season vaccine which contained an A/South Australia/34/2019 (H3N2)-like virus [a clade 3C.2a1b/T131K virus]

For further details: https://www.who.int/influenza/vaccines/virus/recommendations/2021_south/en/

G. Additional Information

Explanatory Note:

The surveillance period for the 2020-21 influenza season is defined starting in week 40. Weeks 36-39 of the 2019-20 season are shown on graphs for comparison purposes.

List of Acronyms:

ACF: Acute Care Facility

EV/RV: Enterovirus/Rhinovirus

FHA: Fraser Health Authority

HA: Health authority

HBoV: Human bocavirus

HMPV: Human metapneumovirus

HSDA: Health Service Delivery Area

IHA: Interior Health Authority

ILI: Influenza-Like Illness

LTCF: Long-Term Care Facility

MSP: BC Medical Services Plan

NHA: Northern Health Authority

NML: National Microbiological Laboratory

PHL: Public Health Laboratory

RSV: Respiratory syncytial virus

VCHA: Vancouver Coastal Health Authority

VIHA: Vancouver Island Health Authority

WHO: World Health Organization

Web Sites:

BCCDC Emerging Respiratory Pathogen Updates:

www.bccdc.ca/health-professionals/data-reports/emerging-respiratory-virus-updates

Influenza Web Sites

Canada – Influenza surveillance (FluWatch): <https://www.canada.ca/en/public-health/services/diseases/flu-influenza/influenza-surveillance.html>

Canada – Human Emerging Respiratory Pathogens Bulletins: <https://www.canada.ca/en/public-health/services/surveillance/human-emerging-respiratory-pathogens-bulletin.html>

Washington State Flu Updates: <http://www.doh.wa.gov/portals/1/documents/5100/420-100-fluupdate.pdf>

USA Weekly Surveillance Reports: www.cdc.gov/flu/weekly/

Joint ECDC – WHO/Europe weekly influenza update (Flu News Europe): flunewseurope.org

WHO – Influenza Updates: https://www.who.int/influenza/surveillance_monitoring/updates/en/

WHO – Weekly Epidemiological Record: www.who.int/wer/en/

WHO Collaborating Centre for Reference and Research on Influenza (Australia): www.influenzacentre.org/

Australian Influenza Report:

www.health.gov.au/internet/main/publishing.nsf/content/cda-surveil-ozflu-flucurr.htm

New Zealand Influenza Surveillance Reports: www.surv.esr.cri.nz/virology/influenza_weekly_update.php

Avian Influenza Web Sites

WHO – Influenza at the Human-Animal Interface: www.who.int/csr/disease/avian_influenza/en/

World Organization for Animal Health: www.oie.int/eng/en_index.htm

Contact Us:

Tel: (604) 707-2510

Fax: (604) 707-2516

Email: InfluenzaFieldEpi@bccdc.ca

Communicable Diseases & Immunization Service (CDIS)

BC Centre for Disease Control, 655 West 12th Ave, Vancouver BC V5Z 4R4

Online: www.bccdc.ca/health-professionals/data-reports/influenza-surveillance-reports

Link to fillable Facility Outbreak Report Form: [http://www.bccdc.ca/resource-](http://www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Forms/Epid/Influenza%20and%20Respiratory/OutbreakReportForm_2018.pdf)

[gallery/Documents/Guidelines%20and%20Forms/Forms/Epid/Influenza%20and%20Respiratory/OutbreakReportForm_2018.pdf](http://www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Forms/Epid/Influenza%20and%20Respiratory/OutbreakReportForm_2018.pdf)